GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tanke Biosciences TNBI · USD

N/A · US listing · 🇺🇸 United States

Compare

0.03

0.00%

Close of 5 Nov 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$8,430

FY2021FY2025

Net income

−$274,464

FY2021FY2025

Free cash flow

−$36,990

FY2021FY2025

Shareholders' equity

−$398,806

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Revenue$8,430————
Gross profit$6,866−$977−$8,500——
Operating income−$257,865−$117,421−$94,160−$128,179−$668,030
Net income−$274,464−$119,931−$82,521−$98,150−$722,984
Diluted earnings per share-0.01-0.00-0.00-0.00-0.06

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets$74,471$65,522$69,156$7,318$41,495
Cash and short-term investments$6,013—$2,656$7,318$41,495
Total liabilities$473,277$248,864$164,811$95,452$101,479
Debt$140,000$140,000$140,000$53,027$1,795
Shareholders' equity−$398,806−$183,341−$95,655−$88,134−$59,984
Shares outstanding25m25m21m21m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−$36,987−$34,900−$74,662−$59,177−$3,530
Capital spending−$3—−$2−$3—
Free cash flow−$36,990−$34,900−$74,664−$59,180−$3,530

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue————$8,430———
Gross profit———−$391$7,842−$586−$585−$196
Operating income−$44,593−$35,686−$46,572−$57,767−$61,470−$90,301−$43,861−$22,511
Net income−$47,236−$38,336−$49,222−$60,417−$65,844−$98,881−$57,645−$22,511
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$72,428$78,014$74,471$84,543$101,648$103,203$65,522$66,109
Cash and short-term investments$3,969$9,556$6,013$20,584$37,298$38,267——
Debt$140,000$140,000$140,000$140,000$140,000$140,000$140,000$150,095
Shareholders' equity−$484,378−$437,142−$398,806−$349,585−$289,068−$238,123−$183,341−$152,714

Growth per year

Compound annual rate

3 years5 years10 years
Revenue——-51.7%
Operating income26.2%—29.2%
Net income40.9%—28.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.5-0.3-0.1-0.0-0.0
Price to sales15.1————

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return700%329%20%-79%6433%2300%700%1700%100%0%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 8.512-to-1 reverse split · 10 Feb 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.